Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exosomes derived from mesenchymal stem cells improved core symptoms of genetically modified mouse model of autism Shank3B.

Molecular autism - 17 Aug 2020

Perets N, Oron O, Herman S, Elliott E, Offen D

Abstract excerpt

BACKGROUND: Partial or an entire deletion of SHANK3 are considered as major drivers in the Phelan-McDermid syndrome, in which 75% of patients are diagnosed with autism spectrum disorder (ASD). During the recent years, there was an increasing interest in stem cell therapy in ASD, and specifically, mesenchymal stem cells (MSC). Moreover, it has been suggested that the therapeutic effect of the MSC is mediated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Intranasal
Share to Autistic Disorder
Share to Blood-Brain Barrier

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exosomes

Share to gamma-Aminobutyric Acid

Share to Mesenchymal Stem Cells

Share to Microfilament Proteins

Share to Social Behavior

Source

Open in PubMed Open full text

Identifiers

PMID: 32807217
DOI: 10.1186/s13229-020-00366-x
PMCID: PMC7433169

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exosomes derived from mesenchymal stem cells improved core symptoms of genetically modified mouse model of autism Shank3B.PMID 32807217Read ↗

Exosomes derived from mesenchymal stem cells improved core symptoms of genetically modified mice model of autism Shank3BSemantic proximity Read ↗

Extracellular Vesicles from Stem cells Rescue Cellular Phenotypes and Behavioral Deficits in SHANK3-Associated ASD Neuronal and Mouse ModelsSemantic proximity Read ↗

Extracellular vesicles from stem cells rescue cellular phenotypes and behavioral deficits in SHANK3-associated ASD neuronal and mouse models.Semantic proximity Read ↗

Comparison of SHANK3 deficiency in animal models: phenotypes, treatment strategies, and translational implications.Semantic proximity Read ↗

Autism Spectrum Disorders: Is Mesenchymal Stem Cell Personalized Therapy the Future?Semantic proximity Read ↗

Shank3 mutation impairs glutamate signaling and myelination in ASD mouse model and human iPSC-derived OPCs.Semantic proximity Read ↗

Blood exosome sensing via neuronal insulin-like growth factor-1 regulates autism-related phenotypes.Semantic proximity Read ↗

Inhibition of TRPV4 rescues circuit and social deficits unmasked by acute inflammatory response in a Shank3 mouse model of AutismSemantic proximity Read ↗

Targeting synaptic plasticity and acetylcholine dysregulation in the medial prefrontal cortex: Rosmarinic acid attenuates Autism-like phenotypes in Shank3B-/- mice via the CREB/BDNF pathway.Semantic proximity Read ↗

Pharmacological, non-pharmacological and stem cell therapies for the management of autism spectrum disorders: A focus on human studies.Semantic proximity Read ↗

Unraveling the Role of Neuroligin3 in Autism Spectrum Disorders: Pathophysiological Insights and Targeted Therapies.Semantic proximity Read ↗

Early Restoration of Shank3 Expression in Shank3 Knock-Out Mice Prevents Core ASD-Like Behavioral Phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.